INmune Bio Inc (INMB) Stock Analysis

INmune Bio Inc (INMB) is a publicly traded company in the HEALTHCARE sector. It trades at $1.39, carries a market capitalization of $36.95M. This page summarizes the public market data, fundamentals, and frequently asked questions for INMB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.39
• Market Cap: $36.95M
• EPS: $-1.63
• 52-Week High: $8.29
• 52-Week Low: $1.09

Market Sentiment

INmune Bio Inc currently has a Bullish sentiment score of 0.20.

About INmune Bio Inc

INmune Bio Inc., based in La Jolla, California, is a pioneering clinical-stage immunotherapy company focusing on reprogramming the innate immune system to tackle challenging diseases such as cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. With a promising pipeline of innovative therapies, INmune Bio is strategically positioned to lead advancements in immunotherapy, leveraging the body’s natural defenses to achieve better clinical outcomes. The company’s unwavering commitment to...

GNG Research Analysis

GNG Research scores INmune Bio Inc (INMB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for INMB.

Frequently Asked Questions

Does INMB pay dividends?

INmune Bio Inc (INMB) does not currently pay a regular dividend.

What is INMB's market cap?

INmune Bio Inc (INMB) has a market capitalization of $36.95M with a current stock price of $1.39.